CN100372926C - Pseudomonas putida and application thereof for mandelic acid racemate resolution - Google Patents

Pseudomonas putida and application thereof for mandelic acid racemate resolution Download PDF

Info

Publication number
CN100372926C
CN100372926C CNB2006100823771A CN200610082377A CN100372926C CN 100372926 C CN100372926 C CN 100372926C CN B2006100823771 A CNB2006100823771 A CN B2006100823771A CN 200610082377 A CN200610082377 A CN 200610082377A CN 100372926 C CN100372926 C CN 100372926C
Authority
CN
China
Prior art keywords
acid
cgmcc
application
mandelic acid
pseudomonas putida
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006100823771A
Other languages
Chinese (zh)
Other versions
CN1924003A (en
Inventor
许建和
黄汉荣
徐毅
潘江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East China University of Science and Technology
Original Assignee
East China University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East China University of Science and Technology filed Critical East China University of Science and Technology
Priority to CNB2006100823771A priority Critical patent/CN100372926C/en
Publication of CN1924003A publication Critical patent/CN1924003A/en
Application granted granted Critical
Publication of CN100372926C publication Critical patent/CN100372926C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a Pseudomonas putida ECU1009 (CGMCC No.1388) and application to degrade R-mandelic acid specially.

Description

Pseudomonas putida and the application in mandelic acid racemate resolution thereof
This case is for dividing an application the applying date of original application: on 06 23rd, 2005, and application number: 200510027088.7, denomination of invention: bacillus, pseudomonas putida and the application in mandelic acid racemate resolution thereof.
Technical field
The present invention relates to strain pseudomonas putida and uses thereof.
Technical background
Amygdalic acid (Alpha-hydroxy toluylic acid) is a kind of important pharmacy intermediate.Than the raceme of amygdalic acid, the use value of its single enantiomer (dextrorotation or left-handed amygdalic acid) is higher.Therefore, the single enantiomer that how can simple and effective ground obtains amygdalic acid becomes the research focus.
United States Patent (USP) 4,322,548 have mentioned a kind of optical activity phenylglycine ester and phenylglycine ester hydrochloride of utilizing as resolving agent, reach the purpose that splits amygdalic acid by forming diastereomer with amygdalic acid, the shortcoming of this method is to use expensive chiral separation agent and a large amount of organic solvents, and splitting step is more loaded down with trivial details; Document J.Chem.Soc.Perkin TransI.1992,2253-2255 has reported lipase catalysis transesterification fractionation amygdalic acid and derivative thereof in organic phase, obtain optical purity 〉=97%ee (S)-(+)-amygdalic acid and 〉=(R)-(-)-amygdalic acid of 99%ee, but the shortcoming of this method is that the reaction times is longer, and transformation efficiency is not high; Document Appl.Environ.Microbiol.1991,57 (10), 3028-3032 has reported and has utilized Bacillus foecalis alkaligenes cell catalysis raceme mandelonitrile selective hydrolysis to generate optical purity (R)-(-)-amygdalic acid that its shortcoming is to have potential safety hazard.Therefore, how can be easy, safety and the single enantiomer that obtains amygdalic acid efficiently become the technical issues that need to address of the present invention.
Summary of the invention
One of the object of the invention is, the bacterial strain of energy selectivity degraded (R)-(-)-amygdalic acid is provided;
Two of the object of the invention is, a kind of method of using the above-mentioned bacterial strains mandelic acid racemate resolution is provided.
The present inventor is from soil, through primary dcreening operation, multiple sieve and separation and purification, obtain bacillus (Bacillus sp.) ECU1008 of (S)-(+) enantiomorph in the strain energy selectivity degraded racemize amygdalic acid, this bacterial strain is preserved in China Committee for Culture Collection of Microorganisms common micro-organisms center (CGMCC) on June 8th, 2005, and preserving number is: CGMCC No.1387; Equally, the contriver obtains pseudomonas putida (Pseudomonas putida) ECU1009 of (R)-(-) enantiomorph in another strain energy selectivity degraded racemize amygdalic acid from soil by screening, this bacterial strain is preserved in China Committee for Culture Collection of Microorganisms common micro-organisms center (CGMCC) on June 8th, 2005, and preserving number is: CGMCC No.1388.
CGMCC No.1387 bacterial strain has following feature:
1, size and form
Shaft-like, size 2～3 μ m, shuttle shape gemma, Gram-positive are produced in cultivation after a couple of days in producing the gemma substratum;
2, be fit to growing environment
Can be 10～40 ℃ of temperature, survive in pH5～9, NaCl concentration 0～7% (w/v) environment;
3, the dull and stereotyped bacterium colony characteristic of cultivating
Concentric circles; Prominent umbilical; Yellow.
CGMCC No.1388 bacterial strain has following feature:
1, size and form
Shaft-like, size 2～3 μ m do not produce gemma, Gram-negative;
2, be fit to growing environment
Can be 10～40 ℃ of temperature, survive in pH5～9, NaCl concentration 0～7% (w/v) environment;
3, the dull and stereotyped bacterium colony characteristic of cultivating
Circle, neat in edge; Low convex surface; Oyster white.
CGMCC No.1387 bacterial strain or the application of CGMCC No.1388 bacterial strain in mandelic acid racemate resolution, its key step is as follows:
CGMCC No.1387 bacterial strain or CGMCC No.1388 bacterial strain are seeded to biotransformation medium by 1～10v/v% inoculum size, in 20～40 ℃ of (preferred 25～35 ℃) states down keep 1～5 day (preferred 2～3 days) after centrifugal after removing thalline water, regulate the gained aqueous pH values less than after 3, after extraction (R)-(-)-or (S)-(+)-amygdalic acid;
Wherein: said biotransformation medium is: racemize amygdalic acid 0.1～5wt%, corn steep liquor 0.1～2wt%, NH 4NO 30.1～0.5wt%, K 2HPO 40.1～0.5wt%, KH 2PO 40.1～0.5wt%, NaCl0.1～0.5wt%, MgSO 40.1～0.5wt%, surplus is a water.
In the present invention, CGMCC No.1387 bacterial strain or CGMCC No.1388 bacterial strain are preferably in before being used for mandelic acid racemate resolution by glucose 0.1～3wt%, peptone 0.1～3wt%, yeast extract paste 0.1～3wt%, racemize amygdalic acid 0.1～3wt%, K 2HPO 40.1～0.5wt%, KH 2PO 40.1～0.5wt%, NaCl0.1～0.5wt%, MgSO 40.1～0.5wt%, agar 0～2wt% and surplus are to cultivate in advance in the pre-culture medium formed of water, 20～40 ℃ of pre-incubated temperature, and the pre-incubated time is 1～6 day.
Utilize two strain bacteriums disclosed by the invention and similar technology, can also split the raceme of mandelic acid derivatives, as parahydroxymandelic acid, parachloromandelic acid, a chloro mandelic acid and o-Chloromelic acid isoracemization body.
Adopt the used bio-conversion process of the present invention, can not only obtain simply and easily highly purified (R)-or (S)-amygdalic acid, and production cost is lower than the prior art, is a kind of production method with wide application prospect, can satisfy the needs of the medicine industry that develops rapidly.
Embodiment
By the following examples technology contents of the present invention is further described.Its purpose only is better to understand content of the present invention, and unrestricted protection scope of the present invention:
Embodiment 1
The screening of bacterial strain
The soil diluent supernatant that takes a morsel is coated with flat board, and (contain enrichment medium, it consists of: benzoyl formic acid 2.0g, (NH 4) 2SO 42.0g, K 2HPO 41.0g, NaCl1.0g, MgSO 40.5g, agar 20g, tap water 1000ml, pH7.0), be inverted down at 25～40 ℃ and cultivated 2～4 days, choose single bacterium on the rich medium flat board, to cultivate 1～2 day, again with single colony inoculation to liquid fermentation medium (glycerine 15.0g, peptone 5.0g, yeast extract paste 5.0g, K 2HPO 41.0g, KH 2PO 41.0g, NaCl1.0g, MgSO 40.5g, tap water 1000ml, pH7.0) middle cultivation is 24 hours, centrifugal collection bacterial strain Bacillus sp.ECU1008 or Pseudomonas putida ECU1009.
Embodiment 2
With Bacillus sp.ECU1008 (CGMCC No.1387) inoculation to 40ml growth medium (glucose 1.5wt%, peptone 0.5wt%, yeast extract paste 0.5wt%, K2HPO40.1wt%, KH2PO40.1wt%, NaCl0.1wt%, MgSO 40.05wt%, all the other are water, pH7.0) in, on 30 ℃, 160rpm shaking table pre-cultivate 12h after, add 0.5% racemize amygdalic acid as inductor, continue to cultivate 12h; With this nutrient solution is seed, is seeded to 40ml by the inoculum size of 10v/v% and transforms substratum (racemic mandelic acid 20.0g, corn steep liquor 1.0g, NH 4NO 3, K 2HPO 41.0g, KH 2PO 41.0g, NaCl1g, MgSO 40.5g, water 1000ml, pH7.0) in, 30 ℃ of following 160rpm shaking table top fermentations transform 2 days.Reaction finishes the back with the centrifugal 10min of 10000 * g, collect supernatant liquor, rotary evaporation is removed most of water, with 50% sulfuric acid acidation concentrated solution to pH1～2, saturated with salt again, ethyl acetate extraction, anhydrous sodium sulfate drying, rotary evaporation fall organic solvent and get crystal crude product, by silica gel column chromatography (benzene: ethyl acetate: formic acid, volume ratio 10: 2: 1) behind the purifying, gets pure product (R)-amygdalic acid 380mg, productive rate 46.5%.
Embodiment 3
With Pseudomonasputida ECU1009 (CGMCC No.1388) inoculation to 40m1 nutritional medium (glucose 1.5wt%, peptone 0.5wt%, yeast extract paste 0.5wt%, K 2HPO 40.1wt%, KH 2PO 40.1wt%, NaCl0.1wt%, MgSO 40.05wt%, all the other are water, pH7.0) in, the pre-12h that cultivates on 30 ℃, 160rpm shaking table, adding 0.5% amygdalic acid as inductor, continue to cultivate 12h, is seed with this nutrient solution, inoculum size by 10% is seeded to 40ml and transforms substratum (racemic mandelic acid 10.0g, corn steep liquor 1.0g, NH 4NO 3, K 2HPO 41.0g, KH 2PO 41.0g, NaCl1g, MgSO 40.5g, tap water 1000ml, pH7.0) in, cultivated on 28 ℃ of following 160rpm shaking tables 2 days.Reaction finishes the centrifugal 10min of back 10000 * g, remove thalline, keep supernatant liquor, add the 1g activated carbon and add heat decoloring, remove by filter activated carbon, filtrate rotary evaporation under reduced pressure is removed most of water, vitriol oil acidifying concentrated solution is to pH1～2, saturated with salt, ethyl acetate extraction, anhydrous sodium sulfate drying, rotary evaporation falls organic solvent and gets crystal crude product, behind silica gel column chromatography (benzene: ethyl acetate: formic acid, volume ratio 10: 2: 1) purifying, get pure product (S)-amygdalic acid 350mg, productive rate 42.0%.
Embodiment 4
With Bacillus sp.ECU1008 (CGMCC No.1387) inoculation to 40ml nutritional medium (glucose 1.5wt%, peptone 0.5wt%, yeast extract paste 0.5wt%, K 2HPO 40.1wt%, KH 2PO 40.1wt%, NaCl0.1wt%, MgSO 40.05wt%, all the other are water, pH7.0) in, the pre-12h that cultivates on 30 ℃, 160rpm shaking table, adding 0.5% amygdalic acid as inductor, continue to cultivate 12h, is seed liquor with this nutrient solution, inoculum size by 10% is seeded to 200ml and transforms substratum (racemic mandelic acid 10.0g, corn steep liquor 1.0g, NH 4NO 3, K 2HPO 41.0g, KH 2PO 41.0g, NaCl1.0g, MgSO 40.5g, tap water 1000ml, pH7.0) in, cultivate on 30 ℃ of following 160rpm shaking tables, when 21h, 34h and 58h, add the 2g racemic mandelic acid, and transfer pH with strong aqua, it is remained between 6.5～7.0, finish after 94 hours to transform.
In the whole process, monitoring thalli growth situation is with the optical density(OD) (OD value) of spectrophotometric determination fermented liquid under 600nm.The measuring method of amygdalic acid concentration: sample 1ml is answered in negate, centrifuging and taking 0.1ml supernatant, and adding 0.1ml1M HCl solution, 0.2ml10mM toluylic acid methanol solution and 0.4ml methanol mixed are even, use the concentration of reversed-phase HPLC post assay products amygdalic acid then; 0.4ml with the acidifying of 0.1ml1.0M HCI solution, extracted with diethyl ether, behind the evaporation dry diethyl ether, carry out esterification, use chiral chromatographic column (Chiracel OD) to analyze the enantiomeric excess value (ee) of methyl mandelate then with trimethylchlorosilane.Reverse-phase chromatographic column is used Shim-Pack VP-ODS (Shimadzu, 150 * 4.6mm); Moving phase be methyl alcohol/KH2PO4 aqueous solution (13/87, v/v; 0.8ml/min); The 225nm ultraviolet detection.Amygdalic acid, benzoyl formic acid, phenylformic acid and interior target appearance time are respectively 6.5,9.2,24.8 and 29.9min.Adopt chiral chromatographic column (Chiracel OD, Daicel Co., Japan) analyze the methyl mandelate enantiomeric excess value, moving phase is normal hexane/Virahol=(90:10, v/v, 0.7ml/min), peak sequence is followed successively by methyl benzoylformate (8.5min), (S)-methyl mandelate (12.0min), (R)-methyl mandelate (20.0min); The 228nm ultraviolet detection.
After the fermentation ends under 10000 * g condition centrifugal 10min separate and remove cell, get the 420ml supernatant and transfer pH to 5.0, add the 1g activated carbon and add heat decoloring, remove by filter activated carbon, the most of water of filtrate decompression rotary evaporation, obtain the 94ml concentrated solution, add the acidifying of the 4ml vitriol oil, use 40ml ethyl acetate extraction four times, combining extraction liquid, reduction vaporization falls solvent, coarse crystallization, with twice in 15ml toluene recrystallization.Get (R)-amygdalic acid 6.5g, productive rate 40%, [α] after the drying D 20=-152.0 °.
Embodiment 5
With Pseudomonas putida ECU1009 (CGMCC No.1388) inoculation to 40ml nutritional medium (glucose 1.5wt%, peptone 0.5wt%, yeast extract paste 0.5wt%, K 2HPO 40.1wt%, KH 2PO 40.1wt%, NaCl0.1wt%, MgSO40.05wt%, all the other are water, pH7.0) in, the pre-12h that cultivates adds 0.5% amygdalic acid as inductor on 30 ℃, 160rpm shaking table, continues to cultivate 12h; With this nutrient solution is seed liquor, and the inoculum size by 10% is seeded to 200ml and transforms substratum (racemic mandelic acid 10.0g, corn steep liquor 1.0g, NH 4NO 3, K 2HPO 41.0g, KH 2PO 41.0g, NaCl1g, MgSO 40.5g, tap water 1000ml, pH7.0) in, cultivate on 30 ℃ of following 160rpm shaking tables, add the 1g racemic mandelic acid respectively at 21h, 34h, 45h and 58h, and regulate pH with strong aqua, it is remained between 6.5～7.0.Finish after 94 hours to cultivate.The concentration determination of fermenting process amygdalic acid is with embodiment 4.
Ferment to transform and finish back centrifugal 10min under 10000 * g condition, separate and remove cell, get the 440ml supernatant, transfer pH to 5.0, add the 1g activated carbon and add heat decoloring, remove by filter activated carbon, the most of water of filtrate decompression rotary evaporation, obtain the 94ml concentrated solution, add the acidifying of the 4ml vitriol oil, use 40ml ethyl acetate extraction 4 times, combining extraction liquid, reduction vaporization falls solvent, gets coarse crystallization, and recrystallization is twice in 15ml toluene.Get (S)-amygdalic acid 4.95g, productive rate 41%, [α] after the drying D 20=+152.2 °.

Claims (4)

1. a strain pseudomonas putida (Pseudomonas putida) ECU1009, its preserving number is: CGMCC No.1388.
2. the application of bacterial strain as claimed in claim 1 in mandelic acid racemate resolution.
3. application as claimed in claim 2, it is characterized in that, the key step of described mandelic acid racemate resolution is: CGMCC No.1388 bacterial strain is seeded to biotransformation medium by 1～10v/v% inoculum size, in 20～40 ℃ of states kept 1～5 day down after centrifugal after removing thalline water, regulate the gained aqueous pH values less than after 3, after extraction (S)-(+)-amygdalic acid;
Wherein: said biotransformation medium is: racemize amygdalic acid 0.1～5wt%, corn steep liquor 0.1～2wt%, NH 4NO 30.1～0.5wt%, K 2HPO 40.1～0.5wt%, KH 2PO 40.1～0.5wt%, NaCl0.1～0.5wt%, MgSO 40.1～0.5wt%, surplus is a water.
4. application as claimed in claim 3 is characterized in that wherein CGMCC No.1388 bacterial strain is before being used for mandelic acid racemate resolution, by glucose 0.1～3wt%, peptone 0.1～3wt%, yeast extract paste 0.1～3wt%, racemize amygdalic acid 0.1～3wt%, K 2HPO 40.1～0.5wt%, KH 2PO 40.1～0.5wt%, NaCl 0.1～0.5wt%, MgSO 40.1～0.5wt%, agar 0～2wt% and surplus are to cultivate in advance in the pre-culture medium formed of water, 20～40 ℃ of pre-incubated temperature, and the pre-incubated time is 1～6 day.
CNB2006100823771A 2005-06-23 2005-06-23 Pseudomonas putida and application thereof for mandelic acid racemate resolution Expired - Fee Related CN100372926C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006100823771A CN100372926C (en) 2005-06-23 2005-06-23 Pseudomonas putida and application thereof for mandelic acid racemate resolution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006100823771A CN100372926C (en) 2005-06-23 2005-06-23 Pseudomonas putida and application thereof for mandelic acid racemate resolution

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN 200510027088 Division CN1283783C (en) 2005-06-23 2005-06-23 Bacillus, malodor pseudomonads and their use in splitting amygdalinic acid raceme

Publications (2)

Publication Number Publication Date
CN1924003A CN1924003A (en) 2007-03-07
CN100372926C true CN100372926C (en) 2008-03-05

Family

ID=37816829

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006100823771A Expired - Fee Related CN100372926C (en) 2005-06-23 2005-06-23 Pseudomonas putida and application thereof for mandelic acid racemate resolution

Country Status (1)

Country Link
CN (1) CN100372926C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103013949A (en) * 2013-01-11 2013-04-03 华东理工大学 Acetylation hydroxy acid hydrolase, gene and application thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101684071B (en) * 2008-09-25 2012-12-26 上海宝钢化工有限公司 Method for splitting DL-p-hydroxymandelic acid
CN101538542B (en) * 2009-04-22 2010-12-29 华东理工大学 Pseudomonad esterase and application in preparing optical pure mandel and derivative thereof
CN102660470B (en) * 2012-04-13 2013-07-31 浙江工业大学 Sinorhizobium fredii and its application in producing chiral alpha-hydroxy acid by biologically splitting alpha-hydroxy acid raceme

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06181795A (en) * 1992-04-08 1994-07-05 Bio-Le Kk Production of @(3754/24)r)-mandelic acid
JPH06253890A (en) * 1993-03-01 1994-09-13 Bio-Le Kk Production of (r)-mandelic acid
JPH1099078A (en) * 1996-09-30 1998-04-21 Kaiyo Bio Technol Kenkyusho:Kk R-(-)-mandelic monooxygenase gene
CN1275077A (en) * 1997-10-14 2000-11-29 伊莱利利公司 Process to make chiral compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06181795A (en) * 1992-04-08 1994-07-05 Bio-Le Kk Production of @(3754/24)r)-mandelic acid
JPH06253890A (en) * 1993-03-01 1994-09-13 Bio-Le Kk Production of (r)-mandelic acid
JPH1099078A (en) * 1996-09-30 1998-04-21 Kaiyo Bio Technol Kenkyusho:Kk R-(-)-mandelic monooxygenase gene
CN1275077A (en) * 1997-10-14 2000-11-29 伊莱利利公司 Process to make chiral compound

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103013949A (en) * 2013-01-11 2013-04-03 华东理工大学 Acetylation hydroxy acid hydrolase, gene and application thereof
CN103013949B (en) * 2013-01-11 2014-11-12 华东理工大学 Acetylation hydroxy acid hydrolase, gene and application thereof

Also Published As

Publication number Publication date
CN1924003A (en) 2007-03-07

Similar Documents

Publication Publication Date Title
Zhao et al. Biotransformation of isoeugenol to vanillin by Bacillus fusiformis CGMCC1347 with the addition of resin HD-8
CN101338287B (en) Bacillus subtilis esterase and application thereof for producing 1-menthol
CN100372926C (en) Pseudomonas putida and application thereof for mandelic acid racemate resolution
CN102382780B (en) Microbacterium oxydans and method for preparing chiral bis(trifluoromethyl) phenyl ethanol by using same
CN101134943B (en) Bacillus alcaligenes and method for preparing single enantiomer amygdalic acid
CN101538542B (en) Pseudomonad esterase and application in preparing optical pure mandel and derivative thereof
CN1283783C (en) Bacillus, malodor pseudomonads and their use in splitting amygdalinic acid raceme
WO2014045299A2 (en) Continuous biotransformation of substituted aromatic carboxylic acids to their selective aldehydes and alcohols
CN103589665B (en) Celebrating sheng, a reed pipe wind instrument rhodococcus and the application in preparation (S)-4-chloro-3-hydroxyl ethyl butyrate thereof
CN101824438B (en) Method for preparing (S)-3-hydroxy butyric acid ethyl ester through ethyl acetoacetate microbial conversion
CN102465159B (en) Synthesis process for preparing eslicarbazepine with microbial method
CN100554403C (en) Oxidation microbacterium and utilize this oxidation microbacterium to prepare the method for optical pure chiral aryl secondary alcohol
Miyazawa et al. Asymmetric reduction of karahanaenone with various microorganisms
CN102031237B (en) Stenotrophomonas and method for preparing 1-menthol and application thereof
CN102994403B (en) Rhodotorula glutinis and application of Rhodotorula glutinis in preparation of (R)-2-hydroxy-4- phenyl ethyl butyrate through asymmetric catalysis
CN102071231B (en) Method for preparing S-(+)-3-hydroxy tetrahydrofuran through microbial conversion
CN102586349B (en) Preparation method of ethyl (R)-2-hydroxyl-4-phenylbutyrate by combining microbe reduction and chemical catalytic hydrogenation
CN102925500A (en) Preparation method of chiral 4-hydroxy-4 phenyl butyric acid ester
CN101709271B (en) Saccharomyces cerevisiae and application thereof in preparing (R)-(+)-beta-hydroxy-benzenepropanoic acid ethylester by microbial transformation
CN1132928C (en) Two-saccharomycetes strains and its usage in preparing optically pure 2-aryl propionic acid
CN101985609B (en) Pseudomonas and method for performing microbial transformation on pregabalin intermediate by using same
CN104561136A (en) Method for converting racemate aryl ortho-diol into chiral aryl ortho-diol
CN103642849A (en) Method of asymmetrically reducing 1-acetonaphthone to optically pure (S)-1-naphthyl-1-ethanol and screening method
CN115975826A (en) Saccharomyces cerevisiae mSte 003 and application thereof in production of beta-arbutin
Ou et al. ASYMMETRIC SYNTHESIS ATOMOXETINE INTERMEDIATE (R)-ETHYL 3-HYDROXY-3-PHENYLPROPIONATE WITH MICROORGANISMS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Assignee: Qidong Dongyue Pharmacy Co., Ltd.

Assignor: East China University of Science and Technology

Contract fulfillment period: 2008.3.15 to 2013.3.14 contract change

Contract record no.: 2008320000529

Denomination of invention: Pseudomonas putida and application thereof for mandelic acid racemate resolution

Granted publication date: 20080305

License type: Exclusive license

Record date: 2008.10.6

LIC Patent licence contract for exploitation submitted for record

Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.3.15 TO 2013.3.14; CHANGE OF CONTRACT

Name of requester: QIDONG DONGYUE PHARMACY CO., LTD.

Effective date: 20081006

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080305

Termination date: 20100623